Most promising are the three novel classes of mediations which have thus far been largely studied in adult patients: GLP1 receptor agonists, DPP4 inhibitors, and SGLT2 inhibitors, as well as dietary approaches to reverse diabetes and its associated complications (e.g., VLEDs). This evidence concerns the gene SLC5A2 and diabetes mellitus.